Nifty
Sensex
:
:
24946.50
81796.15
227.90 (0.92%)
677.55 (0.84%)

Pharmaceuticals & Drugs

Rating :
71/99

BSE: 543322 | NSE: ALIVUS

1018.00
16-Jun-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1014.2
  •  1028
  •  1003.7
  •  1014.20
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  99404
  •  100484168
  •  1335.1
  •  819.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 12,494.07
  • 25.73
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 12,422.83
  • 0.49%
  • 4.43

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.99%
  • 1.79%
  • 10.50%
  • FII
  • DII
  • Others
  • 6.57%
  • 3.81%
  • 2.34%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 8.23
  • 2.45

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 7.39
  • 1.82

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 8.50
  • 3.99

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 16.08

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 3.73

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 12.82

Earnings Forecasts:

(Updated: 06-06-2025)
Description
2024
2025
2026
2027
Adj EPS
38.43
39.63
45.47
53.92
P/E Ratio
26.49
25.69
22.39
18.88
Revenue
2283
2387
2660
3053
EBITDA
674
683
791
939
Net Income
471
486
557
661
ROA
17
15.5
17.4
19
P/B Ratio
5.35
4.43
3.95
3.40
ROE
21.07
18.86
18.37
19
FCFF
297
243
184
307
FCFF Yield
2.35
1.92
1.45
2.43
Net Debt
-284
-492
20
-98
BVPS
190.35
229.75
257.83
299.55

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated
Description
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Net Sales
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Expenses
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
EBITDA
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
EBIDTM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Other Income
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Interest
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Depreciation
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PBT
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Tax
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PAT
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PATM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
EPS
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

News Update:


  • USFDA issues EIR with Voluntary Action Indicated status for Alivus Life Sciences’ API unit
    4th Apr 2025, 14:50 PM

    The said API unit is located in GIDC Industrial Estate in the state of Gujarat

    Read More
  • Alivus Life Sciences inks pact with Torrent Urja 19
    3rd Apr 2025, 14:12 PM

    The company’s promoter company -- Nirma will acquire minimum 16.99% stake in Torrent Urja 19

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.